Show simple item record

dc.contributor.authorToffoli, M
dc.contributor.authorChohan, H
dc.contributor.authorMullin, S
dc.contributor.authorJesuthasan, A
dc.contributor.authorYalkic, S
dc.contributor.authorKoletsi, S
dc.contributor.authorMenozzi, E
dc.contributor.authorRahall, S
dc.contributor.authorLimbachiya, N
dc.contributor.authorLoefflad, N
dc.contributor.authorHiggins, A
dc.contributor.authorBestwick, J
dc.contributor.authorLucas-Del-Pozo, S
dc.contributor.authorFierli, F
dc.contributor.authorFarbos, A
dc.contributor.authorMezabrovschi, R
dc.contributor.authorLee-Yin, C
dc.contributor.authorSchrag, A
dc.contributor.authorMoreno-Martinez, D
dc.contributor.authorHughes, D
dc.contributor.authorNoyce, A
dc.contributor.authorColclough, K
dc.contributor.authorJeffries, AR
dc.contributor.authorProukakis, C
dc.contributor.authorSchapira, AHV
dc.date.accessioned2023-11-28T13:28:59Z
dc.date.available2023-11-28T13:28:59Z
dc.date.issued2023-11
dc.identifier.issn0969-9961
dc.identifier.issn1095-953X
dc.identifier.other106343
dc.identifier.urihttps://pearl.plymouth.ac.uk/handle/10026.1/21747
dc.description.abstract

Background Variants in the GBA1 gene cause the lysosomal storage disorder Gaucher disease (GD). They are also risk factors for Parkinson's disease (PD), and modify the expression of the PD phenotype.

The penetrance of GBA1 variants in PD is incomplete, and the ability to determine who among GBA1 variant carriers are at higher risk of developing PD, would represent an advantage for prognostic and trial design purposes.

Objectives To compare the motor and non-motor phenotype of GBA1 carriers and non-carriers.

Methods We present the cross-sectional results of the baseline assessment from the RAPSODI study, an online assessment tool for PD patients and GBA1 variant carriers. The assessment includes clinically validated questionnaires, a tap-test, the University of Pennsyllvania Smell Identification Test and cognitive tests. Additional, homogeneous data from the PREDICT-PD cohort were included.

Results A total of 379 participants completed all parts of the RAPSODI assessment (89 GBA1-negative controls, 169 GBA1-negative PD, 47 GBA1-positive PD, 47 non-affected GBA1 carriers, 27 GD). Eighty-six participants were recruited through PREDICT-PD (43 non-affected GBA1 carriers and 43 GBA1-negative controls). GBA1-positive PD patients showed worse performance in visual cognitive tasks and olfaction compared to GBA1-negative PD patients. No differences were detected between non-affected GBA1 carriers carriers and GBA1-negative controls. No phenotypic differences were observed between any of the non-PD groups.

Conclusions Our results support previous evidence that GBA1-positive PD has a specific phenotype with more severe non-motor symptoms. However, we did not reproduce previous findings of more frequent prodromal PD signs in non-affected GBA1 carriers.

dc.format.extent106343-106343
dc.format.mediumPrint-Electronic
dc.languageen
dc.publisherElsevier BV
dc.subjectParkinson
dc.subjectGBA1
dc.subjectGBA
dc.subjectProdromal
dc.subjectGenetics
dc.titlePhenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study
dc.typejournal-article
dc.typeArticle
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/37926171
plymouth.volume188
plymouth.publisher-urlhttp://dx.doi.org/10.1016/j.nbd.2023.106343
plymouth.publication-statusPublished
plymouth.journalNeurobiology of Disease
dc.identifier.doi10.1016/j.nbd.2023.106343
plymouth.organisational-group|Plymouth
plymouth.organisational-group|Plymouth|Research Groups
plymouth.organisational-group|Plymouth|Faculty of Health
plymouth.organisational-group|Plymouth|REF 2021 Researchers by UoA
plymouth.organisational-group|Plymouth|Users by role
plymouth.organisational-group|Plymouth|Users by role|Academics
plymouth.organisational-group|Plymouth|REF 2021 Researchers by UoA|UoA01 Clinical Medicine
plymouth.organisational-group|Plymouth|Faculty of Health|Peninsula Medical School
plymouth.organisational-group|Plymouth|Research Groups|FoH - Community and Primary Care
plymouth.organisational-group|Plymouth|Research Groups|FoH - Applied Parkinson's Research
plymouth.organisational-group|Plymouth|Users by role|Researchers in ResearchFish submission
plymouth.organisational-group|Plymouth|REF 2028 Researchers by UoA
plymouth.organisational-group|Plymouth|REF 2028 Researchers by UoA|UoA01 Clinical Medicine
dc.publisher.placeUnited States
dcterms.dateAccepted2023-11-01
dc.date.updated2023-11-28T13:28:51Z
dc.rights.embargodate2023-12-6
dc.identifier.eissn1095-953X
rioxxterms.versionofrecord10.1016/j.nbd.2023.106343


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV